Disease · MONDO_0019136

Zygomycosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Zygomycosis. Diseases, record MONDO_0019136. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019136

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Zygomycosis; Open Targets
Open Targets ID: MONDO_0019136; Open Targets
Other names: Mucormycosis, Mucormycosis (disorder), Mucormycosis, unspecified, Mucormycosis, unspecified (disorder), Phycomycosis or Mucormycosis, Zygomycosis (disorder), Zygomycosis [Phycomycosis or Mucormycosis], Zygomycosis, unspecified (disorder), Zygomycota infectious disease, disseminated mucormycosis; Open Targets
Disease Ontology: DOID:8485; Disease Ontology
MeSH: D009091; MeSH
MeSH: D020096; MeSH
NCI Thesaurus: C77212; NCI Thesaurus
Orphanet: ORPHA:73263; Orphanet
Highest stage of its drugs: Approval, for 3 of its 5 drugs, from DailyMed and PMDA; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMPHOTERICIN B	CHEMBL267345	Small molecule	Approval	DailyMed	6	5	5	Drugs and targets
ISAVUCONAZONIUM SULFATE	CHEMBL3137333	Small molecule	Approval	DailyMed and PMDA	4	2	2	Drugs and targets
POSACONAZOLE	CHEMBL1397	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
DEFERASIROX	CHEMBL550348	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ISAVUCONAZOLE	CHEMBL409153	Small molecule	Unknown	ClinicalTrials.gov	4	4	4	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04550936	A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.		307	2025-12-09	Invasive Aspergillosis, Mucormycosis	ISAVUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03816176	A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants	Phase 2	31	2023-09-21	Invasive Mucormycosis, Invasive Aspergillosis	ISAVUCONAZONIUM SULFATE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00419770	The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study	Phase 2	20	2011-10-06	Mucormycosis	AMPHOTERICIN B, DEFERASIROX	Its record names the disease	ClinicalTrials.gov
NCT07191756	Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study		150		Mucormycosis	AMPHOTERICIN B, ISAVUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03471988	Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis	Phase 3	103		Deep Mycosis	ISAVUCONAZONIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT04744454	Post Marketing Surveillance (PMS) Study of Cresemba in Korea.		94		Aspergillosis, Mucormycosis	ISAVUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT07185503	Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety		60		Mucormycosis in Hematologic Malignancies	AMPHOTERICIN B, ISAVUCONAZOLE, POSACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00467883	Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment	Phase 2	40		Zygomycosis	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov
NCT04502381	Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis	Phase 2	30		Pulmonary Mucormycosis	AMPHOTERICIN B	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Isavuconazole Administered as Part of Combination Therapy	53 of 254	27 of 44	298	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 24	42 of 201	3 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Inpatient Hospitalization	114 of 201	14 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 12	38 of 201	3 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 6	48 of 201	1 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 12	30 of 201	3 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants Who Switched to New Antifungal	34 of 201	2 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 6	33 of 201	2 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Any Outpatient Visits	87 of 201	9 of 17	218	NCT04550936	Trial comparisons
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 6	26 of 201	2 of 17	218	NCT04550936	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26316385	RESULT	1	PubMed
39540734	DERIVED	1	PubMed
39443403	DERIVED	1	PubMed
36307059	DERIVED	1	PubMed
35191210	DERIVED	1	PubMed
21937481	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019136

GET https://conductscience.org/api/diseases/v1/MONDO_0019136/drugs

API reference For AI assistants